There are few published data on the recovery of fertility after 'little' Bu-Cy (busulfan 16 mg/kg, cyclophosphamide 120 mg/kg) conditioning for BMT. To address this, we identified 19 females aged less than 40 years at transplant and 47 males from a single centre who were alive a minimum of 2 years after BMT with little Bu-Cy as conditioning and who were evaluable for testing. FSH, LH, testosterone and inhibin B levels were measured in males. Twenty-six also had semen analysis, a median of 5 years post transplant; 21 had detectable sperm, with 11 having counts Ͼ20 × 10 6 /ml. There was an association between prolonged chronic graft-versus-host disease and low sperm counts. FSH and inhibin B levels correlated with sperm counts but not to the extent that they could reliably predict counts in individual patients. An additional six of seven males attempting to father children did so, a median of 3.2 years post transplant. Low testosterone levels were noted in 12% of males, most of whom had symptoms consistent with androgen deficiency. FSH, LH and oestradiol levels in the absence of hormone replacement therapy were measured in females; all remained amenorrheic with endocrine evidence of ovarian failure. These results have implications for fertility counselling and hormone replacement therapy both pre-and post BMT. Bone Marrow Transplantation (2000) 26, 1089-1095. Keywords: busulfan; cyclophosphamide; marrow transplantation; fertility; testosterone Myeloablative conditioning regimens comprising high dose combination alkylating agents have been conventionally considered to cause permanent infertility in the vast majority of adult patients of either sex undergoing allogeneic or autologous marrow or peripheral blood stem cell transplantation. The most widely used non-total body irradiation (TBI) regimen prior to allografting is busulfancyclophosphamide (Bu-Cy). To our knowledge, the only substantial peer-reviewed publication of the effects of BuCy on fertility has been published by the Seattle group in
which busulfan 16 mg/kg was combined with cyclophosphamide 200 mg/kg, so called 'big' Bu-Cy. 1 In this report, only one of 73 females recovered ovarian function, although the median age was relatively old (38 years; range 14-57) and the median follow-up was only 2 years. Testicular recovery (defined as normal luteinizing hormone (LH), follicle stimulating hormone (FSH) and testosterone levels with evidence of sperm production) was reported in eight of 46 (17%) males (median age 34 years; range , with a median follow-up of 2 years.
The dose of cyclophosphamide now generally used in combination with busulfan is 120 mg/kg, so called 'little' Bu-Cy. Copelan et al 2 reported that four of 46 adult males followed-up for at least 2 years after little Bu-Cy had fathered normal children, but no data on semen analysis in this group were provided. We are not aware of any series which has systematically evaluated the recovery of fertility in a large cohort of survivors of either sex following little Bu-Cy.
This paper evaluates ovarian function in 19 females and testicular function in 47 males who survived at least 2 years after a transplant using little Bu-Cy based conditioning. The results demonstrate that the majority of adult men have a degree of spermatogenesis and suggest that prolonged chronic graft-versus-host disease (GVHD) may adversely effect sperm counts. Normal ovarian function was not seen in any female.
Patients and methods
To be eligible for this study, patients had to fulfil the following criteria: (1) Male of any age or female р40 years at time of transplant and Ͻ50 years at time of evaluation. (2) No prolonged alkylator therapy (ie more than 6 months of cyclophosphamide, chlorambucil or melphalan) or other regimens known to be sterilising (eg MOPP or similar combinations 3 ) both before and after transplant. Patients did not routinely have assessment of fertility pre-transplant. (3) At least 2 years since transplant. (4) Conditioning regimen containing little Bu-Cy. Fifteen patients (nine males, six females) received VP16 in addition, given as a continuous infusion over 120 h. 4 (5) In females, no hormonal replacement therapy (HRT) for at least the previous 2 months.
Serum FSH, LH and total testosterone levels were assayed in the males and, where possible, semen was analysed. A semen sample was collected at least 72 h from the last ejaculation and examined within 2 hours of collection. Serum inhibin B levels were measured in 22 males using an ELISA assay as previously described; 5 the lowest level detectable was 4.5 pg/ml. The mean inhibin B value in 39 normal young males was 129 pg/ml with two standard deviation range of 43-390 pg/ml. Serum FSH, LH and oestradiol levels were assayed in the women; inhibin B was not. All patients gave verbal consent to participation in the study.
Extensive chronic GVHD was defined as GVHD beyond day 100 requiring at least 6 months of systemic immunosuppressive therapy with cyclosporin and/or prednisolone. Normal ovarian function was defined as spontaneous menstruation and normal FSH, LH and oestradiol levels without hormone supplement. 1 Reproductive status was also evaluated in a smaller number of patients who fulfilled all the eligibility criteria except that they received a chemotherapy-only conditioning regimen other than Bu-Cy. These regimens consisted of BuMel (busulfan 16 mg/kg, melphalan 140 mg/m . Paired values of hormone levels and sperm counts were assessed by linear regression analysis and Pearson correlation. The association between sperm counts and chronic GVHD was assessed by the Cochran-Armitage trend test.
Results

Males
Fifty males were identified who fulfilled the eligibility criteria. Three were not tested as they could not be contacted. Forty-seven males were evaluated with hormonal profiles. Twenty-six had semen analysed; 21 patients did not have semen analysis, six of whom have fathered children. These groups have been evaluated separately.
The laboratory data on the 26 males with semen analysis are detailed in Table 1 . The underlying condition was acute leukemia or chronic myeloid leukemia (CML) in 23 patients. Four received VP16 in addition to Bu-Cy; the total dose ranged between 250 and 750 mg/m 2 . Seven of eight autograft recipients had at least some sperm in their semen analysis specimens. The median sperm count in these patients was 16 × 10 6 /ml (range 0-84); the single azoospermic patient in this group had received additional pelvic radiotherapy with an estimated 2 Gy scattered dose to the testes.
Fourteen of 18 allograft recipients had detectable sperm. The median counts in patients with (n = 6) and without (n = 12) prolonged chronic GVHD were 0 × 10 6 /ml (range 0-203) and 21 × 10 6 /ml (range Ͻ1-271), respectively. All four azoospermic allograft recipients had prolonged chronic GVHD; none had received pelvic radiotherapy or other immunosuppression (eg thalidomide or total lymphoid irradiation) in addition to cyclosporin and prednisolone. There was a significant trend (P = 0.014; two-sided exact P value) for lower sperm counts in the presence of prolonged chronic GVHD (Table 1) .
Semen analysis immediately prior to transplant was available in four patients, all of whom had sperm present post transplant. The pre-transplant sperm counts were normal in three (5-200 × 10 6 /ml) and low (Ͼ1 × 10 6 /ml) in one patient on concomitant hydroxyurea.
There was no effect of the underlying disease or age at transplant (Table 1 ) on subsequent sperm counts. Two of the four patients who received additional VP16 and who underwent sperm testing were azoospermic, including the azoospermic autograft patient and an allograft recipient with chronic GVHD. Of note, the two patients receiving the highest VP16 doses (1500, 1750 mg/m 2 ) had sperm counts of 8 and 26 × 10 9 /l, respectively. Fourteen of the 26 patients who underwent semen analysis had elevated FSH levels (reference range 1-10.5 U/l. Patients with higher levels were less likely to have detectable sperm (Table 1 and Figure 1 ). Levels were elevated in only two of 11 patients with sperm counts in excess of 20 × 10 9 /l, but in 12 of 15 patients with counts between 0 and 20 × 10 9 /l. However, while all three patients with FSH values Ͼ22 IU/l were azoospermic, levels could not reliably predict sperm counts in most patients with oligospermia or azoospermia. LH levels did not correlate with sperm counts (Table 1 and Figure 2 ). Levels were Ͻ9 IU/l (reference range 1-8.5) in 20 of 21 patients with detectable sperm and in two of five azoospermic patients. In only one of the remaining three azoospermic patients was LH Ͼ11.5 IU/l.
A fine needle testicular biopsy in one of the azoospermic patients with chronic GVHD showed all the seminiferous tubules to be reduced in diameter, with moderate peritubular fibrosis. Some were hyalinized, with no epithelium; other tubules were lined by Sertoli cells only. No germ There was no statistical correlation between the sperm count and the time post transplant at which the analyses was performed. However, one patient, aged 26 years at transplant, underwent serial semen analysis 2.2, 4.8 and 6.8 years post transplant, with sperm counts of 3, 11 and 54 × 10 6 /ml respectively. Another, aged 23 years at transplant, had sperm counts of 7 and 76 × 10 6 /ml, 2.8 and 9.6 years respectively, post transplant.
The results of the additional six patients who subsequently fathered a total of seven children are shown in Table 2 . None has undergone semen analysis. While Table 2 Results on males without semen analysis who fathered children One patient fathered a second child 7 years post BMT.
Results are expressed as median (range).
Bone Marrow Transplantation paternity testing was not carried out, the normal FSH and LH values in each patient are consistent with an expectation of a normal semen analysis. Of note, two of the three allograft recipients in this group had prolonged chronic GVHD. Five of the seven children are male. One has a mild hypospadias and another has magnetic resonance imaging findings suggestive of incomplete type 1 lissencephaly, for which a genetic origin can be demonstrated in most cases. 6 The father of this child has juvenile absence epilepsy. None of the other children have congenital abnormalities. One of the six wives had a miscarriage post transplant before a subsequent normal pregnancy; none of the others have had miscarriages.
The results of 15 male patients who fulfilled the eligibility criteria but did not undergo semen analysis due to pre-transplant vasectomy (n = 8) or refusal (n = 7) are shown in Table 3 . FSH was within the reference range in only four and substantially elevated in three; in contrast LH was within the reference range in 12 (80%) and never elevated more than twice the upper limit of the range. None of the non-vasectomised patients has fathered children. Four have wives who are post-menopausal; a fifth patient has not fathered children despite his wife being pre-menopausal and in the absence of contraception. Details in these Bone Marrow Transplantation respects of the remaining two non-vasectomised patients are not available.
Total serum testosterone levels were measured in 43 of the 47 male patients. The median testosterone value was 12.9 (range 6.2-34.6) nmol/l (reference range 7-28). Five patients (12%), with a median age of 48 years at the time of testing (range 29-58), had values at or below the lower limit of the reference range, one of whom was the patient who had received scattered low-dose radiotherapy to the testes. Details of libido and erectile function were obtained in six of the seven patients with testosterone levels р9 nmol/l. Five had low libido and seldom had spontaneous erections; four are receiving testosterone replacement therapy.
Inhibin B levels were measured in 22 patients, 16 of whom received Bu-Cy ±VP16. There was a significant correlation between inhibin B levels and the sperm count ( Figure 3 ). All five patients with inhibin B levels р16.5 pg/ml were azoospermic; however, four other azoospermic patients had inhibin B levels comparable to those observed in patients with sperm counts between 5-8 × 10 6 /l. While there was no overall significant correlation between inhibin B and testosterone levels (P = 0.52) five of the six patients with inhibin B values р16.5 pg/ml had testosterone values р9 nmol/l; inhibin B levels were 27 and 16 pg/ml in the two other patients with testosterone levels Ͻ9 nmol/l.
Females
We identified 32 female patients who had survived more than 2 years. Results of hormone tests are not available in 13 of this group, all of whom are taking HRT, due to their refusal to cease HRT for testing, intolerable menopausal symptoms within weeks of ceasing HRT necessitating its recommencement, or logistical difficulties. The hormonal profiles of the remaining 19 women, taken after at least 2 months without HRT, are detailed in Table 4 . Most (16 patients) were transplanted for acute leukemia or CML. Six had additional VP16 at a median dose of 750 mg/m 2 (range 250-750). None had received prior pelvic radiotherapy.
None of the tested patients had spontaneous menses and none had an FSH or LH value within the reference range. Only one patient had an oestradiol value above 100 pmol/l (148 pmol/l). Most patients noticed significant menopausal symptoms during their time without HRT and all but one have resumed HRT. No woman in the entire group has conceived naturally. Two women have had children using fertilised ova from their sisters. Testosterone levels were not measured routinely in our female transplant survivors as part of this study; however nine women who were tested had values р0.6 nmol/l (reference range 0.3-3.0 nmol/l), with six (two of whom were receiving glucorticosteroids) Ͻ0.1 nmol/l.
Reproductive status after other conditioning regimens
A small number of surviving patients who received other conditioning regimens was evaluated. Bu-Mel was used in four patients autografted for persistent low-grade nonHodgkin's lymphoma (NHL) and BEAM in six patients autografted for Hodgkin's disease or NHL. None of these patients had received prior chemotherapy with regimens associated with a high risk of sterilisation.
The results in male patients receiving these regimens are detailed in Table 5 . Overall, eight of 10 patients in whom semen was analysed were azoospermic, although the median time post transplant when tested was shorter than the little Bu-Cy group.
Three females have been evaluated post BEAM; the results in two tested at 13 and 14 months, respectively, were consistent with ovarian failure. The third woman, aged 22 years at transplant, conceived naturally 13 months post transplant and has subsequently had two healthy children 22 and 40 months post transplant.
Discussion
Our results demonstrate that the majority of males who have not received sterilising chemotherapy beforehand, who then proceed to BMT using little Bu-Cy as conditioning, will have some detectable sperm post transplant. Combining the results of semen analysis in the tested patients with the assumed fertility of untested males whose wives subsequently had children, 27 of 32 (84%) males demonstrated a degree of spermatogenesis. This incidence appears to be higher than the Seattle experience using 'big' Bu-Cy, 4 with the caveats that the definition of testicular recovery in that report required normal hormonal levels, as well as evidence of sperm production and that the median followup was only 2 years; some males may have subsequently recovered spermatogenesis. This is consistent with a doserelated effect of high-dose cyclophosphamide on germinal epithelium. The addition of continuous infusion VP16 to little Bu-Cy had no obvious deleterious effect on fertility.
It is impossible to draw conclusions about the kinetics Bone Marrow Transplantation of recovery of spermatogenesis as testing occurred a median of 5 years post transplant and all but two of our patients had only a single semen analysis. We were unable to demonstrate a significant effect of age or time from transplant on the sperm count, noting that all patients were at least 2 years post transplant and the numbers are relatively small. The serial sperm counts documented in two young patients, however, suggest that progressive recovery of spermatogenesis may occur over time. This is consistent with the data on four other males, not included in this study, who recently were tested 9-13 months post transplant; all had no or very scanty sperm. We evaluated whether hormonal studies could obviate the need for semen analysis. Serum FSH and LH levels were not reliable predictors in individual patients of the presence and concentration of sperm. LH levels were within or just above the reference range in seven of eight azoospermic patients. FSH levels tended to be low in patients with higher sperm counts, but were normal in only two of 10 patients with detectable sperm at counts Ͻ20 × 10 6 /ml. Inhibin B is a glycoprotein hormone secreted by Sertoli cells which suppresses pituitary FSH secretion. Inhibin B levels are reduced in patients with spermatogenic failure and show a reciprocal relationship with FSH during chemotherapy-induced spermatogenic damage. 7 In our study we observed a significant correlation of inhibin B levels with sperm counts. However, while all five patients with very low inhibin B levels were azoospermic, inhibin B levels did not reliably distinguish the non-azoospermic patients from the other four azoospermic patients.
The combination of inhibin B and FSH levels has been reported to be a more sensitive marker than either alone for detecting absent or severely impaired spermatogenesis. 8, 9 In our study, however, this combination was not particularly discriminating. Three of the four azoospermic patients with inhibin levels between 10 and 20 pg/ml had FSH levels Ͻ20 IU/l, values often seen in patients with detectable sperm. Semen analysis therefore remains the only reliable current method of assessing spermatogenesis.
One factor unexpectedly associated with azoospermia was extensive chronic GVHD. Testicular biopsy in one of these patients demonstrated a Sertoli cell only syndrome, but without tissue biopsies from a number of patients one can only speculate the existence of a spermatogenic disorder. Severe illness can impair spermatogeneis, but other specific processes, such as auto-antibody production against germinal cells, may be involved. One azoospermic patient had normal FSH and inhibin B levels within the normal range, suggesting that an obstructive process may be involved, 10 although such a hormonal profile can exist with spermatogenic failure. More extensive studies, including pre-transplant semen analysis and testicular biopsy, will be required to confirm the relationship of chronic GVHD with azoospermia and to delineate the underlying pathophysiological processes.
Leydig cells are less vulnerable to high-dose chemotherapy than the germinal epithelium. However, in our series, 12% of men had testosterone levels below the reference range, and in a further three the levels were just within the range. These patients had symptoms consistent with androgen deficiency, particularly low libido and rare erections.
Most were also azoospermic, with low inhibin B levels, indicative of associated semiferous epithelial damage. Our results contrast with reported data after 'big' Bu-Cy in which testosterone levels were subnormal in only one of 42 patients. 11 Chatterjee et al 12 however, demonstrated diminished Leydig cell reserve post BMT and noted that males older than 45 years were susceptible to testosterone insufficiency. Four of the five patients with low levels in our study were older than 45 years at the time of testing. Chronic glucorticoid therapy can reduce testosterone levels, 13 but only one of our patients was receiving prednisolone. Temporary but significant falls in testosterone levels in the first 6 months post transplant have recently been reported and may play a role in bone loss during this period. 14 Based on these data, our current recommendations are to advise sexually active heterosexual male patients that they may become fertile within the second year post transplant and that it is likely that a degree of spermatogenesis will resume within the first 5 years. We still, however, recommend sperm cryopreservation prior to transplant in males who may wish to father children subsequently. Annual semen examinations beginning 1 year post transplant are carried out for patients in whom the result is clinically relevant. These are continued at least until the documentation of spermatogenesis and, in consenting patients, to at least 6 years post transplant to evaluate the effect of time on the concentration of sperm. In the minority of patients who are persistently azoospermic at 5 years, we offer semen analysis biennially to detect late recovery. We also routinely measure testosterone levels at 3, 6, 12 and 24 months post transplant and consider androgen replacement if there is significant loss of bone density or symptoms of androgen deficiency.
In contrast to the high incidence of recovery of gonadal function in males, no female in this series had spontaneous recovery of ovarian function. As we did not routinely evaluate hormonal function pre-transplant, it is possible we may be overestimating the impact of BMT on impaired gonadal function. The study was restricted, however, to women р40 years at the time of transplant who had not received prior sterilising chemotherapy. In addition, our observations are broadly consistent with the results from the Seattle series. 1 The greater sterilising effect of 'little' Bu-Cy in females contrasts, however, with the higher incidence of recovery of fertility in females compared with males after non-myeloablative chemotherapy such as MOPP or similar regimens for Hodgkin's disease. 3 The almost inevitability of infertility after Bu-Cy also contrasts with the small chance of recovery of ovarian function after other conditioning regimens. There are reports of pregnancies after cyclophosphamide/total body irradiation, 1 BEAM (in addition to our case), 15 CBV (cyclophosphamide, BCNU and etoposide) 16 and high-dose melphalan. 17 Larger studies are required, however, to evaluate the incidence of recovery of fertility after various conditioning regimens and the effect of variables such as prior treatment and age at transplant. Until the results of larger series are available, we still recommend evaluating post-transplant ovarian function in all women who are pre-menopausal prior to transplant with 'little' Bu-Cy, as we cannot unequivocally conclude on the basis of our study that all such females will become permanently infertile.
In females, infertility as a consequence of 'little' Bu-Cy has implications for counselling pre-transplant with respect to options for subsequent pregnancy. These include cryopreservation of fertilised embryos which when subsequently re-implanted can result in successful pregnancy, 18 and cryopreservation of ovarian tissue and oocyte donation from, in most cases, a sister. Women who are pre-or peri-menopausal at the time of transplant are routinely offered HRT. This improves the symptoms of flushing and may have a beneficial effect on bone density. 19 The significance of the low testosterone levels seen in the majority of these women is unclear. As androgen therapy may be important in female sexuality and in maintaining bone mineral density over and above the effects of oestrogen replacement therapy, 20 women with low testosterone levels and symptoms suggestive of androgen deficiency are referred for specialist endocrinological review. Androgen replacement for females in this context requires further study.
These results have implications for contraceptive practice and the requirement for HRT in transplant survivors. The data from this review and an ongoing multi-centre study in a larger number of transplant patients receiving both myeloablative and non-myeloablative chemotherapy are intended to facilitate appropriate and informed counselling both pre-and post transplant to those patients in whom fertility and sexual function are important issues.
